TAGRISSO 80MG TABLET is used in the management of non-small cell lung cancer (NSCLC) in adults who have epidermal growth factor receptor (EGFR) gene mutation. It contains Osimertinib which is an anticancer agent which works by blocking the actions of EGFR genes which is required by the cancer for growth and multiplication. By blocking its actions, Osimertinib stops NSCLC cancer progression which is specific to EGFR mutation.
TAGRISSO 80MG TABLET should be used under medical supervision. It can be taken with or without food. Do not stop taking TAGRISSO 80MG TABLET without consulting your doctor.
Before taking TAGRISSO 80MG TABLET, inform your doctor if you previously had or currently have any lung problems, heart problems or eye problems, or if you are pregnant or breastfeeding as a precaution.
Men and women of childbearing potential must use a suitable contraceptive agent while taking Osimertinib and until 2 months (for women) and 4 months (for men) to avoid pregnancy. If you accidentally became pregnant while taking TAGRISSO 80MG TABLET, inform your doctor immediately.
The most common side effects of taking TAGRISSO 80MG TABLET are diarrhoea, skin rashes, itching, pain, dryness and redness around fingernails, especially in areas exposed to skin, mouth ulcers, loss of appetite, low WBC and platelet count in the blood, hair thinning, Hand-foot syndrome (causing skin redness, swelling, tingling or burning sensation with cracking of the skin on the palms of hands and/or soles of feet). Consult your doctor if any of these side effects trouble you.
No content available
